$CAH · CARDINAL HEALTH INC
Cardinal Health reported Q1 FY2027 (ended Sept 30, 2026) revenue of $67.5B, up 5% YoY. GAAP operating earnings rose 13% to $753M and GAAP diluted EPS rose 27% to $2.38; non-GAAP operating earnings rose 17% to $1.0B and non-GAAP diluted EPS rose 28% to $3.26. The company raised FY2027 non-GAAP EPS guidance to $12.80–$13.00 and completed a $500M share repurchase program in Q1.
- Revenue rose 5% YoY to $67.5B.
- Non-GAAP diluted EPS rose 28% to $3.26; GAAP EPS rose 27% to $2.38.
- FY2027 non-GAAP EPS guidance raised to $12.80–$13.00 from $12.40–$12.60.
- Pharmaceutical and Specialty Solutions segment profit rose 17% to $783M.
- Global Medical Products and Distribution segment profit fell 28% to $33M.
- Completed $500M accelerated share repurchase in Q1.
Extended-hours last trade $267.01, +1.94% vs regular close of $261.93, reflecting a positive reaction to the beat and raised guidance.
A beat-and-raise quarter with a $500M buyback and CVS distribution renewal signals durable earnings momentum for a $60B+ distributor.
Pharmaceutical distribution peers benefit from brand/specialty volume growth; Cardinal's CVS Health distribution agreement renewal reinforces volume stability.
GMPD segment profit declined 28% on distribution and FX headwinds; DOJ investigations into Anti-Kickback Statute and False Claims Act remain outstanding.